Trince

Ottergemsesteenweg-Zuid 731

9000 Gent

BE

Trince

Foundation date

17/09/2021

Sector

#Supplier & Engineering

Subsector

Trince, a spin-off company from UGent is dedicated to delivering molecules into cells, both in vitro and ex vivo. Its LumiPore transfection platform combines laser exposure and nanoparticles to transiently permeabilize cell membranes. It can be used to deliver a wide variety of effector molecules into virtually any cell type, including hard-to-transfect cells. The high-throughput technology ensures efficient and gentle transfection, maximizing the therapeutic quality of the final cell product.

Latest news

  • P95 Acquires Assign DMB, Expanding Data Management and Biostatistics Services

    Thursday September 5th 2024

  • reMYND appoints new CEO and Chairman to progress novel Alzheimer’s Disease program through clinical development

    Tuesday September 3rd 2024

  • Biotalys Receives Approval for Large-Scale Demonstration Trials of EVOCA in the Netherlands

    Monday September 2nd 2024